Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Hasten Biopharmaceutic

Request full access

Acquiring and commercializing pharmaceuticals for chronic, geriatric diseases

Tangshan City, ChinaFounded 2020Biotech & Life Sciences

About Hasten Biopharmaceutic

Hasten Biopharmaceutical is a biopharmaceutical company established in 2020 that integrates research and development, production, and commercialization. The company was jointly established by investors including CBC Group, an Asian healthcare-dedicated asset management firm, Hefei Industry Investment Group, and Feidong County of Hefei City. The current CEO is Summer Xia, and the Chairman is Honggang Feng.

Hasten's business model centers on acquiring the rights to and commercializing established pharmaceutical products, primarily in the fields of chronic diseases, critical care, and age-related illnesses. The company's strategy involves expanding its product pipeline and geographical footprint through strategic acquisitions. Hasten makes money by marketing and selling these drugs in its licensed territories. A key part of its strategy is to acquire Marketing Authorization Holder (MAH) rights, allowing it to control the commercial future of these products.

Since its founding, Hasten has engaged in several significant acquisitions to build its portfolio. In 2022, it acquired the exclusive rights for five cardiovascular and metabolism drugs from Takeda Pharmaceutical for the mainland China market for $322 million. In 2023, the company acquired the commercial rights in mainland China for Rocephin®, a broad-spectrum antibiotic, from Roche. A major expansion occurred in 2024 when Hasten acquired the asset rights for 14 branded products from the South Korean company Celltrion, expanding its presence across eight Pan-Asian countries and regions. This deal included well-known drugs for hypertension and diabetes such as Edarbi®, Basen®, Actos®, Blopress®, and Nesina®. The company's growth is supported by significant fundraising, including a $315 million round in April 2023 co-led by CBC and the Abu Dhabi sovereign wealth fund, Mubadala Investment Company, to fund acquisitions and pipeline development.

Source: Dealroom company data

Hasten Biopharmaceutic in the Tangshan City ecosystem

Live from Dealroom

The Hasten Biopharmaceutic office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

3 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series B and later3 investors entered at this stage

Team profiled 1 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
4 countries with
team presence
🇨🇳 China69.6%
🇸🇬 Singapore21.7%
🇭🇰 Hong Kong4.3%
🇺🇸 United States4.3%
4 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Hasten Biopharmaceutic on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Hasten Biopharmaceutic on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.